These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9537919)

  • 1. [Perspectives of breast cancer from the ECCO-9 and from the 15th National Convention of Experimental and Clinical Oncology].
    Tumori; 1997; 83(6):979-82. PubMed ID: 9537919
    [No Abstract]   [Full Text] [Related]  

  • 2. Aromatase inhibitors for breast cancer--further progress.
    Rubens RD
    Eur J Cancer; 1997 Jun; 33(7):989-90. PubMed ID: 9376202
    [No Abstract]   [Full Text] [Related]  

  • 3. Advanced breast cancer in elderly patients: which drug after tamoxifen?
    Bajetta E
    Tumori; 2002; 88(1 Suppl 1):S59-60. PubMed ID: 11989927
    [No Abstract]   [Full Text] [Related]  

  • 4. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aromatase inhibitors: a review of clinical trials].
    Kerbrat P; Lefeuvre C
    Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation aromatase inhibitors.
    Bajetta E; Zilembo N; Noberasco C
    Tumori; 1995; 81(2):77-80. PubMed ID: 7778222
    [No Abstract]   [Full Text] [Related]  

  • 8. [Aromatase inhibitors].
    Mauriac L; Bonneterre J
    Bull Cancer; 2000 Dec; 87 Spec No():5. PubMed ID: 11250603
    [No Abstract]   [Full Text] [Related]  

  • 9. Aromatase inhibitors: basic and clinical studies.
    Brodie AM; Coombes RC; Dowsett M
    J Steroid Biochem; 1987; 27(4-6):899-903. PubMed ID: 3320568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aromatase inhibitors: pharmacological aspects].
    de Crémoux P
    Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
    Neves MA; Dinis TC; Colombo G; Sá e Melo ML
    Eur J Med Chem; 2009 Oct; 44(10):4121-7. PubMed ID: 19500885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aromatase inhibitors].
    Feutrie ML; Bonneterre J
    Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
    Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
    Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of preclinical models to the treatment of postmenopausal breast cancer.
    Dukes M
    Oncology; 1997; 54 Suppl 2():6-10. PubMed ID: 9394853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
    Dowsett M
    Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of hormonal treatments for metastatic breast cancer in postmenopausal women.
    Wasaff B
    Oncol Nurs Forum; 1997 Oct; 24(9):1515-20; quiz 1521-2. PubMed ID: 9348592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERBB2 status and outcome of endocrine treatment.
    Miller WR
    Lancet Oncol; 2008 Jan; 9(1):4-5. PubMed ID: 18177812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.